Non-inferiority of silodosin 4mg once daily to twice daily for storage symptoms score evaluated by the International Prostate Symptom Score in Japanese patients with benign prostatic hyperplasia: A multicenter, randomized, parallel-group study

Narihito Seki, Ryosuke Takahashi, Akito Yamaguchi, Kenji Ito, Kazuo Takayama, Kazushige Nanri, Yoriaki Kamiryo, Hiroshi Yamashita, Shinichiro Komine, Yoshiharu Miyazaki, Jiro Uozumi, Seiji Naito

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objectives: To compare the effect of treatment with silodosin 4mg once daily versus that of silodosin 4mg twice daily on storage symptoms in Japanese patients with benign prostatic hyperplasia. Methods: A prospective, multicenter, 12-week, open-labeled study randomized a total of 268 men aged 50years or older with benign prostatic hyperplasia and overactive bladder to silodosin 4mg/day or 8mg/day. Changes in the end-points of the average value of International Prostate Symptom Score, quality of life index in the International Prostate Symptom Score, Overactive Bladder Symptom Score and urodynamic parameters were evaluated. The change in the storage symptom subtotal score of the International Prostate Symptom Score was considered as the primary end-point. Results: Silodosin 4mg/day was not inferior to silodosin 8mg/day in regard to the primary end-point. In contrast, the efficacy of treatment with silodosin 4mg twice daily was greater than that of 4mg once daily, based on both the quality of life index and the Overactive Bladder Symptom Score total score. There was a discrepancy between the scores evaluated using the International Prostate Symptom Score and Overactive Bladder Symptom Score questionnaires. Conclusions: Silodosin 4mg once daily is not inferior to silodosin 4mg twice daily in regard to storage symptoms score evaluated by the International Prostate Symptom Score. In contrast, silodosin 4mg twice daily is more effective on storage symptoms evaluated by the Overactive Bladder Symptom Score than silodosin 4mg once daily.

Original languageEnglish
Pages (from-to)311-316
Number of pages6
JournalInternational Journal of Urology
Volume22
Issue number3
DOIs
Publication statusPublished - Mar 1 2015

Fingerprint

Prostatic Hyperplasia
Prostate
Overactive Urinary Bladder
Quality of Life
silodosin
Urodynamics

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Non-inferiority of silodosin 4mg once daily to twice daily for storage symptoms score evaluated by the International Prostate Symptom Score in Japanese patients with benign prostatic hyperplasia : A multicenter, randomized, parallel-group study. / Seki, Narihito; Takahashi, Ryosuke; Yamaguchi, Akito; Ito, Kenji; Takayama, Kazuo; Nanri, Kazushige; Kamiryo, Yoriaki; Yamashita, Hiroshi; Komine, Shinichiro; Miyazaki, Yoshiharu; Uozumi, Jiro; Naito, Seiji.

In: International Journal of Urology, Vol. 22, No. 3, 01.03.2015, p. 311-316.

Research output: Contribution to journalArticle

Seki, Narihito ; Takahashi, Ryosuke ; Yamaguchi, Akito ; Ito, Kenji ; Takayama, Kazuo ; Nanri, Kazushige ; Kamiryo, Yoriaki ; Yamashita, Hiroshi ; Komine, Shinichiro ; Miyazaki, Yoshiharu ; Uozumi, Jiro ; Naito, Seiji. / Non-inferiority of silodosin 4mg once daily to twice daily for storage symptoms score evaluated by the International Prostate Symptom Score in Japanese patients with benign prostatic hyperplasia : A multicenter, randomized, parallel-group study. In: International Journal of Urology. 2015 ; Vol. 22, No. 3. pp. 311-316.
@article{7c194e55ac8d42ca8b61f2416bf70c07,
title = "Non-inferiority of silodosin 4mg once daily to twice daily for storage symptoms score evaluated by the International Prostate Symptom Score in Japanese patients with benign prostatic hyperplasia: A multicenter, randomized, parallel-group study",
abstract = "Objectives: To compare the effect of treatment with silodosin 4mg once daily versus that of silodosin 4mg twice daily on storage symptoms in Japanese patients with benign prostatic hyperplasia. Methods: A prospective, multicenter, 12-week, open-labeled study randomized a total of 268 men aged 50years or older with benign prostatic hyperplasia and overactive bladder to silodosin 4mg/day or 8mg/day. Changes in the end-points of the average value of International Prostate Symptom Score, quality of life index in the International Prostate Symptom Score, Overactive Bladder Symptom Score and urodynamic parameters were evaluated. The change in the storage symptom subtotal score of the International Prostate Symptom Score was considered as the primary end-point. Results: Silodosin 4mg/day was not inferior to silodosin 8mg/day in regard to the primary end-point. In contrast, the efficacy of treatment with silodosin 4mg twice daily was greater than that of 4mg once daily, based on both the quality of life index and the Overactive Bladder Symptom Score total score. There was a discrepancy between the scores evaluated using the International Prostate Symptom Score and Overactive Bladder Symptom Score questionnaires. Conclusions: Silodosin 4mg once daily is not inferior to silodosin 4mg twice daily in regard to storage symptoms score evaluated by the International Prostate Symptom Score. In contrast, silodosin 4mg twice daily is more effective on storage symptoms evaluated by the Overactive Bladder Symptom Score than silodosin 4mg once daily.",
author = "Narihito Seki and Ryosuke Takahashi and Akito Yamaguchi and Kenji Ito and Kazuo Takayama and Kazushige Nanri and Yoriaki Kamiryo and Hiroshi Yamashita and Shinichiro Komine and Yoshiharu Miyazaki and Jiro Uozumi and Seiji Naito",
year = "2015",
month = "3",
day = "1",
doi = "10.1111/iju.12680",
language = "English",
volume = "22",
pages = "311--316",
journal = "International Journal of Urology",
issn = "0919-8172",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Non-inferiority of silodosin 4mg once daily to twice daily for storage symptoms score evaluated by the International Prostate Symptom Score in Japanese patients with benign prostatic hyperplasia

T2 - A multicenter, randomized, parallel-group study

AU - Seki, Narihito

AU - Takahashi, Ryosuke

AU - Yamaguchi, Akito

AU - Ito, Kenji

AU - Takayama, Kazuo

AU - Nanri, Kazushige

AU - Kamiryo, Yoriaki

AU - Yamashita, Hiroshi

AU - Komine, Shinichiro

AU - Miyazaki, Yoshiharu

AU - Uozumi, Jiro

AU - Naito, Seiji

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Objectives: To compare the effect of treatment with silodosin 4mg once daily versus that of silodosin 4mg twice daily on storage symptoms in Japanese patients with benign prostatic hyperplasia. Methods: A prospective, multicenter, 12-week, open-labeled study randomized a total of 268 men aged 50years or older with benign prostatic hyperplasia and overactive bladder to silodosin 4mg/day or 8mg/day. Changes in the end-points of the average value of International Prostate Symptom Score, quality of life index in the International Prostate Symptom Score, Overactive Bladder Symptom Score and urodynamic parameters were evaluated. The change in the storage symptom subtotal score of the International Prostate Symptom Score was considered as the primary end-point. Results: Silodosin 4mg/day was not inferior to silodosin 8mg/day in regard to the primary end-point. In contrast, the efficacy of treatment with silodosin 4mg twice daily was greater than that of 4mg once daily, based on both the quality of life index and the Overactive Bladder Symptom Score total score. There was a discrepancy between the scores evaluated using the International Prostate Symptom Score and Overactive Bladder Symptom Score questionnaires. Conclusions: Silodosin 4mg once daily is not inferior to silodosin 4mg twice daily in regard to storage symptoms score evaluated by the International Prostate Symptom Score. In contrast, silodosin 4mg twice daily is more effective on storage symptoms evaluated by the Overactive Bladder Symptom Score than silodosin 4mg once daily.

AB - Objectives: To compare the effect of treatment with silodosin 4mg once daily versus that of silodosin 4mg twice daily on storage symptoms in Japanese patients with benign prostatic hyperplasia. Methods: A prospective, multicenter, 12-week, open-labeled study randomized a total of 268 men aged 50years or older with benign prostatic hyperplasia and overactive bladder to silodosin 4mg/day or 8mg/day. Changes in the end-points of the average value of International Prostate Symptom Score, quality of life index in the International Prostate Symptom Score, Overactive Bladder Symptom Score and urodynamic parameters were evaluated. The change in the storage symptom subtotal score of the International Prostate Symptom Score was considered as the primary end-point. Results: Silodosin 4mg/day was not inferior to silodosin 8mg/day in regard to the primary end-point. In contrast, the efficacy of treatment with silodosin 4mg twice daily was greater than that of 4mg once daily, based on both the quality of life index and the Overactive Bladder Symptom Score total score. There was a discrepancy between the scores evaluated using the International Prostate Symptom Score and Overactive Bladder Symptom Score questionnaires. Conclusions: Silodosin 4mg once daily is not inferior to silodosin 4mg twice daily in regard to storage symptoms score evaluated by the International Prostate Symptom Score. In contrast, silodosin 4mg twice daily is more effective on storage symptoms evaluated by the Overactive Bladder Symptom Score than silodosin 4mg once daily.

UR - http://www.scopus.com/inward/record.url?scp=84924746575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924746575&partnerID=8YFLogxK

U2 - 10.1111/iju.12680

DO - 10.1111/iju.12680

M3 - Article

C2 - 25597862

AN - SCOPUS:84924746575

VL - 22

SP - 311

EP - 316

JO - International Journal of Urology

JF - International Journal of Urology

SN - 0919-8172

IS - 3

ER -